a 2015

Expression of VEGF-A by neoplastic cells in T-cell lymphoblastic lymphoma: possible therapeutic implications related to immunomodulatory properties of this cytokine

KŘENOVÁ, Zdenka, Jaroslav ŠTĚRBA, Eliška TVRDÍKOVÁ and Leoš KŘEN

Basic information

Original name

Expression of VEGF-A by neoplastic cells in T-cell lymphoblastic lymphoma: possible therapeutic implications related to immunomodulatory properties of this cytokine

Authors

KŘENOVÁ, Zdenka (203 Czech Republic, guarantor, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), Eliška TVRDÍKOVÁ (203 Czech Republic, belonging to the institution) and Leoš KŘEN (203 Czech Republic, belonging to the institution)

Edition

Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, 2015

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.812

RIV identification code

RIV/00216224:14110/15:00085103

Organization unit

Faculty of Medicine

ISSN

Keywords in English

T-cell lymphoblastic lymphoma

Tags

Změněno: 7/12/2015 14:44, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Background: VEGF-A, well known for its mechanistic angiogenic effect and as a target for antiangiogenic therapeutic drugs, has also potent immunomodulatory characteristics. Namely, it contributes to blockade of dendritic cells maturation and increases a number of regulatory T lymphocytes (Treg’s) in blood and tumor tissues. Conclusion: We found expression of VEGF-A in a majority of cases of T-LL. Because of known immunosuppressive properties of VEGFA, possible adding of antiangiogenic drugs to therapeutic armamentarium in T-LL appears warranted.